Cytek Biosciences Reports Q3 2026 Revenue Growth Driven by U.S. Market and High-End Instruments
Cytek Biosciences reported third-quarter 2026 revenue of $53.2 million, a 2% year-over-year increase. The growth was primarily fueled by strong performance in the U.S. market, where revenue rose 12%, and significant demand for high-end instrument systems like Aurora and Borealis. Academic and government segments saw substantial gains, growing 38% year over year. However, these gains were partially offset by a 25% decline in APAC revenue due to macroeconomic headwinds in China and a 17% decrease in the Biopharma/CRO segment. Despite a GAAP net loss of $6.1 million, the company improved its GAAP gross margin to 59%, aided by manufacturing efficiencies following a transfer to Singapore. The company maintains its full-year 2026 revenue guidance at a midpoint of approximately $209.5 million.
Tickers: $CTKB
Topics: Quarterly Earnings Regional Performance Revenue Growth Segment Analysis